Gerresheimer Secures Support from Creditors, Launches Centor Inc. Sale

Gerresheimer AG, a prominent player in the pharma, biotech, and cosmetics sectors, has successfully garnered strong backing from its creditors. A significant 96% of holders of promissory notes, covering EUR 870 million, have agreed to extend the submission deadline for the audited 2025 financial statements to September 30, 2026. The company's banking partners have also committed to a similar extension, with key debt covenants relaxed through the third quarter of 2026. This agreement occurs amidst the ongoing sale of its U.S. subsidiary, Centor Inc., aimed at optimizing capital and financial structure.

CFO Wolf Lehmann expressed satisfaction with the creditor support, emphasizing its importance for reviewing past transactions and finalizing 2025 statements. The business performance of Gerresheimer in 2026 has met expectations, with solid orders reported. Specific publication dates for financial statements and meetings will be disclosed in due course.